This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Pharmaxis Management
Management criteria checks 4/4
Pharmaxis' CEO is Gary Phillips, appointed in Mar 2013, has a tenure of 10.25 years. total yearly compensation is A$738.36K, comprised of 70.1% salary and 29.9% bonuses, including company stock and options. directly owns 0.033% of the company’s shares, worth $8.26K. The average tenure of the management team and the board of directors is 10.5 years and 5.7 years respectively.
Key information
Gary Phillips
Chief executive officer
AU$738.4k
Total compensation
CEO salary percentage
70.07%
CEO tenure
10.3yrs
CEO ownership
0.03%
Management average tenure
10.5yrs
Board average tenure
5.7yrs
Recent management updates
Recent updates
CEO Compensation Analysis
How has Gary Phillips's remuneration changed compared to Pharmaxis's earnings?
Date
Total Compensation
Salary
Company Earnings
Dec 31 2022
n/a
n/a
AU$2m
Sep 30 2022
n/a
n/a
AU$2m
Jun 30 2022
AU$738k
AU$517k
-AU$2m
Mar 31 2022
n/a
n/a
-AU$16m
Dec 31 2021
n/a
n/a
-AU$12m
Sep 30 2021
n/a
n/a
-AU$1m
Jun 30 2021
AU$683k
AU$444k
-AU$3m
Mar 31 2021
n/a
n/a
AU$5m
Dec 31 2020
n/a
n/a
-AU$4m
Sep 30 2020
n/a
n/a
-AU$13m
Jun 30 2020
AU$559k
AU$440k
-AU$14m
Mar 31 2020
n/a
n/a
-AU$21m
Dec 31 2019
n/a
n/a
-AU$18m
Sep 30 2019
n/a
n/a
-AU$18m
Jun 30 2019
AU$613k
AU$433k
-AU$20m
Mar 31 2019
n/a
n/a
-AU$27m
Dec 31 2018
n/a
n/a
-AU$12m
Sep 30 2018
n/a
n/a
-AU$22m
Jun 30 2018
AU$776k
AU$424k
AU$6m
Mar 31 2018
n/a
n/a
AU$10m
Dec 31 2017
n/a
n/a
-AU$1m
Sep 30 2017
n/a
n/a
AU$7m
Jun 30 2017
AU$799k
AU$423k
-AU$18m
Mar 31 2017
n/a
n/a
-AU$16m
Dec 31 2016
n/a
n/a
-AU$16m
Sep 30 2016
n/a
n/a
-AU$14m
Jun 30 2016
AU$752k
AU$410k
-AU$16m
Compensation vs Market: Gary's total compensation ($USD488.46K) is below average for companies of similar size in the US market ($USD740.57K).
Compensation vs Earnings: Gary's compensation has been consistent with company performance over the past year.
CEO
Gary Phillips (62 yo)
10.3yrs
Tenure
AU$738,361
Compensation
Mr. Gary Jonathan Phillips, BPharm, MBA, serves as Independent Non-Executive Director at Arovella Therapeutics Limited since July 1, 2022. He has been Chief Executive Officer and Managing Director of Pharm...
Leadership Team
Name
Position
Tenure
Compensation
Ownership
Gary Phillips
CEO, MD & Director
10.3yrs
AU$738.36k
0.033% $ 8.3k
David McGarvey
CFO & Company Secretary
20.5yrs
AU$552.04k
0.13% $ 32.2k
Wolfgang Jarolimek
Head of Drug Discovery
10.8yrs
AU$500.34k
0.17% $ 42.8k
Kristen Morgan
Head of Medical & Regulatory Affairs - Alliance Management
no data
AU$308.49k
no data
Jana Baskar
Chief Medical Officer
less than a year
AU$554.26k
no data
Cameron Billingsley
General Counsel
no data
no data
no data
10.5yrs
Average Tenure
59yo
Average Age
Experienced Management: PMXS.F's management team is seasoned and experienced (10.5 years average tenure).
Board Members
Name
Position
Tenure
Compensation
Ownership
Gary Phillips
CEO, MD & Director
10.3yrs
AU$738.36k
0.033% $ 8.3k
Neil Graham
Non-Executive Director
3.1yrs
AU$70.00k
no data
Malcolm McComas
Independent Chairman of the Board
19.9yrs
AU$100.00k
0.34% $ 86.9k
Alan Robertson
Member of Scientific Advisory Board
no data
AU$711.06k
no data
Simon Green
Independent Non-Executive Director
less than a year
no data
no data
Darren Kelly
Member of Scientific Advisory Board
5.7yrs
no data
no data
Kathleen M. Metters
Member of Scientific Advisory Board & Non Executive Director
6yrs
AU$70.00k
0.0028% $ 701.4
Andrew Boyle
Member of Scientific Advisory Board
no data
no data
no data
Jacob George
Member of Scientific Advisory Board
no data
no data
no data
Carol Pollock
Member of Scientific Advisory Board
no data
no data
no data
Hashan De Silva
Non-Executive Director
less than a year
no data
no data
5.7yrs
Average Tenure
66yo
Average Age
Experienced Board: PMXS.F's board of directors are considered experienced (5.7 years average tenure).
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2023/06/06 22:41
End of Day Share Price
2023/03/09 00:00
Earnings
2022/12/31
Annual Earnings
2022/06/30
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Syntara Limited is covered by 9 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.